Keywords
Canabidiol
Saúde Mental
Tratamento.
How to Cite
Abstract
The study highlights the growing global importance of mental health, particularly considering the prevalence of mental disorders such as depression and anxiety. In this context, cannabidiol (CBD) from the Cannabis sativa plant emerges as a potential treatment, given its wide molecular interaction and anxiolytic properties. The reviewed research consistently indicates the positive effects of CBD in reducing anxiety across a variety of conditions, including post-traumatic stress disorder (PTSD) and social anxiety disorder. However, the complex relationship between CBD plasma concentration and its therapeutic effects, along with the lack of detailed data on its pharmacokinetics, underscores the need for more clinical studies to validate its efficacy and safety in various psychiatric conditions. Additionally, CBD presents broad therapeutic potential in other areas such as schizophrenia and Parkinson's disease, as well as its role in modulating brain activity in areas related to anxiety and psychosis. However, the complexity of CBD effects and the need to explore individual differences in treatment response highlight the importance of a broader and more careful approach in investigating its therapeutic effects.
References
ARNOLD, J. C. et al. The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence. Clinical and Translational Science, v. 16, n. 1, 19 out. 2022.
BATALLA, A. et al. The Impact of Cannabidiol on Human Brain Function: A Systematic Review. Frontiers in Pharmacology, v. 11, 21 jan. 2021.
BRASIL. Lei Nº 12.853. Brasília: 14 de agosto de 2013.
FERBER, S. G. et al. The “Entourage Effect”: Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders. Current Neuropharmacology, v. 18, n. 2, p. 87–96, 23 jan. 2020.
GARCÍA-GUTIÉRREZ, M. S. et al. Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. Biomolecules, v. 10, n. 11, 19 nov. 2020.
HASBI, A.; MADRAS, B. K.; GEORGE, S. R. Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review. Brain Sciences, v. 13, n. 2, p. 325, 14 fev. 2023.
KHAN, R. et al. The therapeutic role of Cannabidiol in mental health: a systematic review. Journal of Cannabis Research, v. 2, n. 1, 2 jan. 2020.
KWEE, C. M. et al. Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration–effect relations using the IB-de-risk tool. Journal of Psychopharmacology, v. 36, n. 12, p. 1299–1314, 14 out. 2022.
MELAS, P. A. et al. Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research. International Journal of Molecular Sciences, v. 22, n. 4, p. 1863, 13 fev. 2021.
PAPAGIANNI, E. P.; STEVENSON, C. W. Cannabinoid Regulation of Fear and Anxiety: an Update. Current Psychiatry Reports, v. 21, n. 6, 27 abr. 2019.
STANCIU, C. N. et al. Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review. Psychiatric Services, v. 72, n. 4, p. appi.ps.2020001, 3 fev. 2021.
WRIGHT, M.; DI CIANO, P.; BRANDS, B. Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of Pre-Clinical and Clinical Evidence. Cannabis and Cannabinoid Research, v. 5, n. 3, 3 jan. 2020.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Leonardo Pereira Levada, Késsia Catarina Belizio da Silva, Anna Railla Barbalho Alves, Natália Batista de Lima e Silva, Taísa Francelina Soares, Hugo Flávio Pereira Raposo, Felipe Gonçalves Correia, Thiemy Iwata Passos, Bárbara da Costa Santana Borges, Giovanna Helena da Silva Amaral , Bhav Babani, Leonardo Sobral Torres Bezerra , Gabriella Gulminetti Miranda , Anthonielle Ingrid Peixoto de Oliveira , Ingrid Paola Canto Gomes de Oliveira